Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference
Stealth BioTherapeutics (Nasdaq: MITO) announced that CEO Reenie McCarthy will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021, at 7:00 a.m. ET. The management will also partake in a panel discussing unmet medical needs in macular degeneration, scheduled for 11:00 a.m. ET on the same day. Interested parties can access a live audio webcast via their Investors & News website, with a replay available for 30 days.
Stealth is dedicated to developing therapies for diseases caused by mitochondrial dysfunction, notably their leading candidate, elamipretide.
- None.
- None.
BOSTON, Aug. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021 at 7:00 a.m. ET. Additionally, Stealth's management will also participate in H.C. Wainwright's "Addressing Unmet Medical Needs in Macular Degeneration – Dry AMD and Stargardt Disease" panel at the event on August 17, 2021 at 11:00 a.m. ET.
A live audio webcast of the presentation will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-hc-wainwright-ophthalmology-virtual-healthcare-conference-301352781.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics present at the H.C. Wainwright Ophthalmology Virtual Conference?
What is the focus of the panel Stealth BioTherapeutics will participate in during the conference?
How can I access the webcast of Stealth BioTherapeutics' presentation?
What is the purpose of Stealth BioTherapeutics?
What is Stealth BioTherapeutics' lead product candidate?
